HC Wainwright Issues Negative Forecast for HRMY Earnings

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) – Research analysts at HC Wainwright cut their Q4 2026 earnings per share (EPS) estimates for shares of Harmony Biosciences in a research report issued to clients and investors on Monday, July 20th. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings of $0.89 per share for the quarter, down from their prior estimate of $1.03. HC Wainwright currently has a “Buy” rating and a $55.00 price target on the stock. The consensus estimate for Harmony Biosciences’ current full-year earnings is $3.26 per share.

Harmony Biosciences (NASDAQ:HRMY) last posted its quarterly earnings results on Thursday, May 7th. The company reported $0.55 earnings per share for the quarter, missing analysts’ consensus estimates of $0.76 by ($0.21). Harmony Biosciences had a net margin of 16.20% and a return on equity of 17.19%. The business had revenue of $215.39 million during the quarter, compared to the consensus estimate of $220.84 million. During the same quarter last year, the company posted $0.78 EPS. The firm’s revenue was up 16.6% on a year-over-year basis.

A number of other research analysts have also commented on HRMY. Zacks Research upgraded shares of Harmony Biosciences from a “hold” rating to a “strong-buy” rating in a research note on Monday, July 13th. Truist Financial raised their price objective on shares of Harmony Biosciences from $25.00 to $29.00 and gave the stock a “hold” rating in a research report on Friday, May 8th. Deutsche Bank Aktiengesellschaft boosted their price objective on Harmony Biosciences from $30.00 to $36.00 and gave the stock a “hold” rating in a report on Tuesday, June 30th. Finally, Weiss Ratings raised Harmony Biosciences from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday, June 23rd. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $42.50.

Harmony Biosciences Price Performance

Shares of HRMY opened at $33.50 on Tuesday. The company’s 50-day moving average is $33.53 and its 200-day moving average is $32.64. The company has a debt-to-equity ratio of 0.15, a current ratio of 3.58 and a quick ratio of 3.56. The firm has a market capitalization of $1.94 billion, a PE ratio of 13.51, a PEG ratio of 0.32 and a beta of 0.94. Harmony Biosciences has a fifty-two week low of $25.52 and a fifty-two week high of $40.87.

Institutional Investors Weigh In On Harmony Biosciences

Several hedge funds have recently modified their holdings of HRMY. Ruffer LLP bought a new position in Harmony Biosciences during the fourth quarter worth $1,536,000. CX Institutional boosted its position in Harmony Biosciences by 19.7% during the fourth quarter. CX Institutional now owns 275,809 shares of the company’s stock valued at $10,321,000 after acquiring an additional 45,376 shares during the last quarter. Wedge Capital Management L L P NC acquired a new stake in Harmony Biosciences during the 4th quarter worth about $3,327,000. Wealth Enhancement Advisory Services LLC acquired a new stake in Harmony Biosciences during the 4th quarter worth about $655,000. Finally, SG Americas Securities LLC raised its position in shares of Harmony Biosciences by 4,102.4% in the 4th quarter. SG Americas Securities LLC now owns 961,667 shares of the company’s stock worth $35,986,000 after acquiring an additional 938,783 shares in the last quarter. Institutional investors and hedge funds own 86.23% of the company’s stock.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc is a commercial‐stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences went public in 2020 and trades on the Nasdaq under the ticker HRMY. The company’s mission centers on identifying and advancing medicines that address critical unmet needs in patient populations underserved by existing treatments.

The company’s flagship product is WAKIX (pitolisant), the first and only histamine H3 receptor antagonist/inverse agonist approved by the U.S.